ALNY·Alnylam Pharmaceuticals, Inc.
ALNY|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.32 | - | - |
| Q2'26 | $1.59 | $1.84 | +16.0% |
| Q1'26 | $0.95 | $1.99 | +108.9% |
| Q4'25 | $2.21 | $1.25 | -43.4% |
| Q4'24 | $-0.14 | $0.06 | +142.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.5B | - | - |
| Q2'26 | $1.3B | $1.3B | -4.4% |
| Q1'26 | $1.1B | $1.2B | +2.7% |
| Q4'25 | $1.1B | $1.1B | -3.7% |
| Q4'24 | - | $593M | - |
ALNY|Monthly Returns
Market Data
ALNY Stock Snapshot
- Market cap
- 32.12B
- P/E ratio
- 39.8
- Day range
- $238.51 – $247.10
- News sentiment
- 53/100 · Neutral
- Analyst target
- $371.35 (+55.0%)
- Consensus
- Buy · 40 analysts
Neither side has the upper hand on ALNY right now, and the indicator set reflects that. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Behaviour On Record
What ALNY's own history says about today's numbers
- Realized volatility (21d)
- 42.2% 46th pct
- Below its peak
- -51.2%
- vs 200-day average
- -23.5%
- Up days (1y)
- 48%
Alnylam Pharmaceuticals, Inc. is currently running 42.2% annualised volatility over the last 21 sessions. Measured against ALNY's own 13 years of daily returns rather than a market-wide average, that is the 46th percentile — close to its own typical level, against a typical reading of 43.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
ALNY is trading -51.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -30.6%, and the deepest was -66.9% in 2016. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits -23.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 10th percentile — a narrower gap than it typically runs. Over the past year ALNY closed higher on 48% of sessions, and it is currently 1 session into a falling streak.
On September specifically: over 13 years of records, ALNY finished the month higher 5 of 13 times, with a median return of -1.8% and an average of -0.3%. Its strongest month historically has been August at +9.6% on average, its weakest October at -5.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: ALNY has opened more than 2% away from the prior close in 240 of 3,266 sessions (7.3% of the time), with the largest gaps running +40.9% and -18.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, ALNY moved an average of 3.3% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.8% and a largest of -5.6%.
All figures computed from 3,267 daily closes between 2013-09-19 and 2026-09-18, split-adjusted, recomputed daily. Percentiles are against ALNY's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of ALNY's sector?
Alnylam Pharmaceuticals, Inc. sits in the Health Care sector, currently ranked 4th of 11 GICS sectors by relative-strength rotation score (improving).
- Sector rank
- #4 of 11
- Sector state
- Improving
- Sector rotation score
- 100
Analyst Rating Changes
Are analysts turning bullish or bearish on ALNY?
Jefferies most recently reiterated its rating on Alnylam Pharmaceuticals, Inc. to Hold on Sep 8, 2026 with a price target of $260 (from $230). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- Jefferies — Hold
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
ALNY Competitive Positioning
- ALNYyou're hereAlnylam Pharmaceuticals, Inc.$32.1B+0.06%
- REGNRegeneron Pharmaceuticals, Inc.$80.6B+0.01%
- BNTXBioNTech SE$24.1B+0.97%
- TECHBio-Techne Corporation$11.3B-0.14%
- RXRXRecursion Pharmaceuticals Inc.$1.7B-0.78%
- DNAGinkgo Bioworks Holdings Inc.$470.7M-0.13%